A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19

Inclusion Criteria: 1. Age ≥ 14 years old; 2. Diagnosed with CD19+B-cell acute lymphoblastic leukemia \[refer to the Chinese Guidelines for Diagnosis and Treatment of Adult Acute lymphoblastic Leukemia (2024 edition)\]; 3. Patients who have received treatment with CNCT-19. Exclusion Criteria: 1. Individuals with acute graft-versus-host disease (GVHD) or moderate to severe chronic GVHD within the first 4 weeks of screening; Individuals who have received systemic drug therapy for GVHD within the past 4 weeks prior to reinfusion; 2. Active systemic autoimmune diseases during treatment; 3. Those who meet any of the following criteria: * Positive hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg); * hepatitis B e antibody (HBe Ab) and/or hepatitis B core antibody (HBc Ab) are positive, and the number of HBV-DNA copies is greater than the measurable lower limit; * Hepatitis C antibody (HCV Ab) positive; * Positive for Treponema pallidum antibody (TP Ab); * Positive human immunodeficiency virus (HIV) antibody test; * EBV-DNA and CMV-DNA copy numbers are greater than the measurable lower limit; 4. Individuals known to have a history of hypersensitivity reactions to the components of the formulation used in the experiment.